198 related articles for article (PubMed ID: 29212069)
21. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
22. Valproic acid inhibits angiogenesis in vitro and in vivo.
Michaelis M; Michaelis UR; Fleming I; Suhan T; Cinatl J; Blaheta RA; Hoffmann K; Kotchetkov R; Busse R; Nau H; Cinatl J
Mol Pharmacol; 2004 Mar; 65(3):520-7. PubMed ID: 14978230
[TBL] [Abstract][Full Text] [Related]
23. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Happold C; Gorlia T; Chinot O; Gilbert MR; Nabors LB; Wick W; Pugh SL; Hegi M; Cloughesy T; Roth P; Reardon DA; Perry JR; Mehta MP; Stupp R; Weller M
J Clin Oncol; 2016 Mar; 34(7):731-9. PubMed ID: 26786929
[TBL] [Abstract][Full Text] [Related]
24. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?
Hoffmann K; Czapp M; Löscher W
Epilepsy Res; 2008 Oct; 81(2-3):107-13. PubMed ID: 18538545
[TBL] [Abstract][Full Text] [Related]
25. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
26. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
[TBL] [Abstract][Full Text] [Related]
27. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
28. Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms.
Chen Y; Tsai YH; Tseng SH
J Neurooncol; 2012 Aug; 109(1):23-33. PubMed ID: 22528797
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Shao CJ; Wu MW; Chen FR; Li C; Xia YF; Chen ZP
Chin Med J (Engl); 2012 Dec; 125(24):4338-43. PubMed ID: 23253698
[TBL] [Abstract][Full Text] [Related]
30. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
31. Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Garcia CG; Kahn SA; Geraldo LHM; Romano I; Domith I; Silva DCLE; Dos Santos Assunção F; Ferreira MJ; Portugal CC; de Souza JM; Romão LF; Netto ADP; Lima FRS; Cossenza M
Mol Neurobiol; 2018 Aug; 55(8):6816-6833. PubMed ID: 29349577
[TBL] [Abstract][Full Text] [Related]
32. Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion.
Wong R; Chen W; Zhong X; Rutka JT; Feng ZP; Sun HS
J Cell Physiol; 2018 Jan; 233(1):363-370. PubMed ID: 28262948
[TBL] [Abstract][Full Text] [Related]
33. Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells.
Wong R; Turlova E; Feng ZP; Rutka JT; Sun HS
Oncotarget; 2017 Feb; 8(7):11239-11248. PubMed ID: 28061441
[TBL] [Abstract][Full Text] [Related]
34. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Watanabe S; Kuwabara Y; Suehiro S; Yamashita D; Tanaka M; Tanaka A; Ohue S; Araki H
Eur J Clin Pharmacol; 2017 Mar; 73(3):357-363. PubMed ID: 27889835
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Camphausen K; Cerna D; Scott T; Sproull M; Burgan WE; Cerra MA; Fine H; Tofilon PJ
Int J Cancer; 2005 Apr; 114(3):380-6. PubMed ID: 15578701
[TBL] [Abstract][Full Text] [Related]
36. Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Proske J; Walter L; Bumes E; Hutterer M; Vollmann-Zwerenz A; Eyüpoglu IY; Savaskan NE; Seliger C; Hau P; Uhl M
Anticancer Res; 2016 Mar; 36(3):899-905. PubMed ID: 26976976
[TBL] [Abstract][Full Text] [Related]
37. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
[TBL] [Abstract][Full Text] [Related]
39. Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Xi W; Chen X; Sun J; Wang W; Huo Y; Zheng G; Wu J; Li Y; Yang A; Wang T
Med Sci Monit; 2018 Feb; 24():1034-1043. PubMed ID: 29457966
[TBL] [Abstract][Full Text] [Related]
40. Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Yagi C; Tatsuoka J; Sano E; Hanashima Y; Ozawa Y; Yoshimura S; Yamamuro S; Sumi K; Hara H; Katayama Y; Yoshino A
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36281939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
